Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature
Cancer Medicine · 2024-08 · 13 (15)
DOI: 10.1002/cam4.7429 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 12.08.2024. Verfasst von Gerald A Soff und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Miami Health System/Sylvester Comprehensive Cancer Center, Miami, Florida, USA. Hauptthemen laut MEDLINE: Receptors, Fc, Thrombopoietin, Recombinant Fusion Proteins, Thrombocytopenia. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy‐induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care. Besides changing anticancer regimens, standard management of CIT has been limited to platelet transfusions and supportive care. Use of the thrombopoietin receptor agonist romiplostim, already approved for use in immune thrombocytopenia, has shown promising signs of efficacy in CIT. In a phase 2 prospective randomized study of solid tumor patients with platelet counts 100 × 10 9 /L in 93% (14/15) of patients within 3 weeks versus 12.5% (1/8) of untreated patients ( p < 0.001). Including patients treated with romiplostim in an additional single‐arm cohort, 85% (44/52) of all romiplostim‐treated patients responded with platelet count correction within 3 weeks. Several retrospective studies of CIT have also shown responses to weekly romiplostim, with the largest study finding that poor response to romiplostim was predicted by tumor invasion of the bone marrow (odds ratio, 0.029; 95% CI: 0.0046–0.18; p < 0.001), prior pelvic irradiation (odds ratio, 0.078; 95% CI: 0.0062–0.98; p = 0.048), and prior temozolomide treatment (odds ratio 0.24; 95% CI: 0.061–0.96; p = 0.043). Elsewhere, lower baseline TPO levels were predictive of romiplostim response ( p = 0.036). No new safety signals have emerged from romiplostim CIT studies. Recent treatment guidelines, including those from the National Comprehensive Cancer Network, now support consideration of romiplostim use in CIT. Data are expected from two ongoing phase 3 romiplostim CIT trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Miami Health System/Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
- Center for Hematology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
- Section of Hematology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Amgen Inc., Thousand Oaks, California, USA.
ORCID-Profile: Gerald A Soff
Förderung
- NCI NIH HHS
Zitieren
APA
Soff, G. A., Al-Samkari, H., Leader, A., Eisen, M., & Saad, H. (2024). Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature. Cancer Medicine, 13(15). https://doi.org/10.1002/cam4.7429
Vancouver
Soff GA, Al-Samkari H, Leader A, Eisen M, Saad H. Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature. Cancer Medicine. 2024;13(15). doi:10.1002/cam4.7429
BibTeX
@article{Soff2024,
author = {Soff, Gerald A and Al-Samkari, Hanny and Leader, Avi and Eisen, Melissa and Saad, Hossam},
title = {Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {15},
doi = {10.1002/cam4.7429}
}
EUVIMED